EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma

Chen, Xiao; Wang, Xuan; Xue, Wei; Wang, Jiandong

doi:10.1186/s13048-016-0292-1

Cited by 21 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EphA5 was negatively expressed in 30/110 (27.3%) and positively expressed in 80/110 (72.3%) samples from patients with gastric cancer. Although the specificity of the anti-EphA5 antibody was confirmed in an ovarian cancer study (21), the absence of a positive control is a limitation of the present study. EphA5 protein expression was reduced in the majority of gastric cancer tissue samples, compared with non-tumor gastric epithelia.…”

Section: Discussionmentioning

confidence: 79%

“…In a previous study, it was determined that EphA5 was expressed in the normal fallopian tube (100%), benign epithelial ovarian tumor cases (100%) and the majority of ovarian serous borderline tumor cases (76%) (5). Reduction of EphA5 expression was observed in ovarian serous carcinoma cases (31%) and was associated with tumor grade and International Federation of Gynecology and Obstetrics stage (21). In the present study, immunohistochemistry (IHC) was performed to evaluate EphA5 protein expression in a set of specimens from patients with gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Changes in the expression patterns of these receptors and their ligands may be associated with alterations in tumor behavior, including increased invasiveness, metastatic potential and angiogenesis, and consequently these changes may also be associated with poor patient outcome. EphA5 is differentially expressed in breast, prostate, lung, ovarian and colorectal cancer types (18)(19)(20)(21)(22). In a previous study, it was determined that EphA5 was expressed in the normal fallopian tube (100%), benign epithelial ovarian tumor cases (100%) and the majority of ovarian serous borderline tumor cases (76%) (5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

et al. 2019

Self Cite

View full text Add to dashboard Cite

The aim of the present study was to evaluate ephrin type-A receptor 5 (EphA5) expression and its clinicopathological significance in gastric cancer. Gastric cancer tissues were analyzed by immunohistochemistry. The association between EphA5 expression and clinicopathological parameters, human epidermal growth factor receptor 2 (HER2) status and Ki-67 proliferation index was statistically analyzed. EphA5 expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 was negatively expressed in 30/110 (27.3%) and positively expressed in 80/110 (72.3%) samples from patients with gastric cancer. EphA5 expression was significantly associated with Lauren classification (P= 0.032), lymph node metastasis (P<0.001), HER2 expression (P=0.020) and Ki-67 expression (P=0.005). No significant association was determined between EphA5 expression and age, sex, primary location, depth of invasion and Tumor-Node-Metastasis stage. The present data indicated that EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that EPHA5 is abnormally expressed in many tumors, such as prostate, ovarian, renal cell, colorectal, and breast cancer, and is inversely correlated with patient prognosis (17, 28). However, there is very little research regarding the role of EPHA5 in the prognosis of patients with HER2‐positive breast cancer who received trastuzumab treatment.…”

Section: Discussionmentioning

confidence: 99%

EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell‐like properties

Chu

Feng

et al. 2019

FASEB j.

View full text Add to dashboard Cite

Trastuzumab is a successful, rationally designed therapy that provides significant clinical benefit for human epidermal growth factor receptor‐2 (HER2)‐positive breast cancer patients. However, about half of individuals with HER2‐positive breast cancer do not respond to trastuzumab treatment because of various resistance mechanisms, including but not limited to: 1) shedding of the HER2 extracellular domain, 2) steric hindrance (e.g., MUC4 and MUC1), 3) parallel pathway activation (this is the general mechanism cited in the quote above), 4) perturbation of downstream signaling events (e.g., PTEN loss or PIK3CA mutation), and 5) immunologic mechanisms (such as FcR polymorphisms). EPHA5, a receptor tyrosine kinase, has been demonstrated to act as an anticancer agent in several cancer cell types. In this study, deletion of EPHA5 can significantly increase the resistance of HER2‐positive breast cancer patients to trastuzumab. To investigate how EPHA5 deficiency induces trastuzumab resistance, clustered regularly interspaced short palindromic repeat technology was used to create EPHA5‐deficient variants of breast cancer cells. EPHA5 deficiency effectively increases breast cancer stem cell (BCSC)‐like properties, including NANOG, CD133+, E‐cadherin expression, and the CD44+/CD24−/low phenotype, concomitantly enhancing mammosphere‐forming ability. EPHA5 deficiency also caused significant aggrandized tumor malignancy in trastuzumab‐sensitive xenografts, coinciding with the up‐regulation of BCSC‐related markers and intracellular Notch1 and PTEN/AKT signaling pathway activation. These findings highlight that EPHA5 is a potential prognostic marker for the activity of Notch1 and better sensitivity to trastuzumab in HER2‐positive breast cancer. Moreover, patients with HER2‐positive breast cancers expressing high Notch1 activation and low EPHA5 expression could be the best candidates for anti‐Notch1 therapy.—Li, Y., Chu, J., Feng, W., Yang, M., Zhang, Y., Zhang, Y., Qin, Y., Xu, J., Li, J., Vasilatos, S. N., Fu, Z., Huang, Y., Yin, Y. EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell–like properties. FASEB J. 33, 4851–4865 (2019). http://www.fasebj.org

show abstract

“…According to the performance of HUVECs overexpressing the above two candidate TFs and change in the mRNA levels of candidate genes, we assumed that SPDEF could act through EPHA5, ZBTB46, or SASH1 to act as a suppressor in HUVECs, while SOX4 has a promoting effect through regulating MMP12 and HIVEP3. Decreased EPHA5 level is associated with poorer tumor prognosis [35,36], and SASH1 acts as a tumor suppressor [37]. ZBTB46 likely has an inhibitory role in angiogenesis [38].…”

Section: Discussionmentioning

confidence: 99%

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Chen

et al. 2020

Epigenomics

View full text Add to dashboard Cite

Aim: This study was conducted to reveal epigenetic landscape in infantile hemangiomas (IHs) and identify transcription factors (TFs) and their downstream genes active in IHs. Materials & methods: We performed Assay for Transposase Accessible Chromatin (ATAC-seq) with RNA-seq in three pairs of IHs and their adjacent normal tissues. Functions of candidate TFs were investigated in human umbilical vein endothelial cells (HUVECs). Results: Chromatin of IH tissues is less compact. Some candidate genes and TFs were identified. In HUVECs, SPDEF inhibited cell viability and tube formation, and promoted apoptosis; SOX4 exerted the opposite effect. SPDEF may act through EPHA5, ZBTB46 and SASH1; SOX4 may act through MMP12 and HIVEP3. Conclusion: Epigenetics plays a role in IHs. SPDEF and SOX4 may act in IHs.

show abstract

EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma

Cited by 21 publications

References 22 publications

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell‐like properties

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Contact Info

Product

Resources

About